Authors: Chan MK, Crichton S, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kityo CM, Ahimbisibwe GM, Variava E, Violari A, Cotton M, Archary M, Cressey TR, Puthanakit T, Bandi S, Bwakura-Dangarembizi M, Bbuye D, Atwine L, Kaudha E, White E, Giaquinto C, Rojo P, Gibb DM,...
Search
results
Search
ResultsPregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert
Authors: Ahimbisibwe G, Wyncoll J, Mngqibisa R, White E, Bwakura-Dangarembizi M, Kekitiinwa AR, Lugemwa A, Kityo CM, Variava E, Liberty A, Kataike H, Ngampiyaskul C, Cotton MF, Riault Y, Archary M, Smit T, Puthanakit T, Shakeshaft C, Nhema R, Bbuye D, Atwine L, Kaudha...
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial
Authors: Wyncoll J, Archary M, Kamolrattana R, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Puthanakit T, Königs C, Behuhuma O, Welch S, Saïdi Y, Marques L, Ahimbisibwe GM, Holden L, Giaquinto C, Rojo P, Gibb DM, Turkova...
Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials
Authors: Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey RT, Ndebele W, Mulenga V, Mwamabazi M, Szubert A, White...
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
Authors: White E, Kityo C, Spyer MJ, Mujuru HA, Nankya I, Kekitiinwa AR, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton MF, Ahimbisibwe GM, Cressey TR, Ngampiyaskul C, Srirompotong U, Behuhuma O, Saidi Y, Bamford A, Kobbe R, Nastouli E, Rojo P, Giaquinto...
ODYSSEY 192-week follow-up evidences superior efficacy of DTG for children on first/second-line ART
Authors: Mujuru AH, White E, Kekitiinwa A, Lugemwa A, Kityo C, Musoke P, Cressey RT, Variava E, Violari A, Archery M, Cotton M, Puthanakit T, Rojo P, Turkova A Presented at: CROI 2024 Read
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial
Authors: Barlow-Mosha L.N., Ahimbisibwe G.M., Chappell E., Amuge P.M., Nanduudu A., Kaudha E., Amukele T., Balamusani D., Kafufu B., Nimwesiga A., Kataike H., Namwanje R., Kasangaki G., Mulindwa A., Muzorah, G.A., Bbuye D., Musiime V., Mujyambere E., Ssenyonga M.,...
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
Authors: Turkova A, White E, Kekitiinwa RA, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe MG, Moloantoa T, Srirompotong U, Mosia RN, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi FM, Klein N, Mujuru AH,...
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
Authors: Amuge P, Lugemwa A, Wynne B, Mujuru AH, Violari A, Kityo MC, Archary M, Variava E, White E, Turner MR, Shakeshaft C, Ali S, Nathoo JK, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa RA,...
Dolutegravir-based HIV treatment is better for babies and young children
Babies and young children treated with the anti-HIV drug dolutegravir, in combination with other anti-HIV drugs, are more likely to keep the virus under control, compared to those treated with standard anti-HIV treatment combinations. This is according to results from...

